Results 1 to 10 of about 4,078 (132)
Therapy-related myeloid neoplasms following peptide receptor radionuclide therapy for neuroendocrine neoplasms: case series reporting characteristics and outcomes from single-centre experience [PDF]
Endocrine OncologyObjective: Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTATATE is increasingly used in the treatment of metastatic neuroendocrine neoplasms (NENs). Marrow toxicity resulting in therapy-related myeloid neoplasms (t-MNs) remains a rare but
Wallace Chow +10 more
doaj +2 more sources
Journal of Child Psychology and Psychiatry, EarlyView.Background Pre‐ and postpartum environments and genetic effects influence childhood internalising problems, which increase depression risk. DNA methylation (DNAm) may capture some of these effects. We therefore investigated associations between child blood DNAm and internalising problems.
Laura Schellhas +9 more
wiley +1 more source
Pharmaceutics, 2022 Aim: The most suitable method for assessment of response to peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NET) is still under debate. In this study we aimed to compare size (RECIST 1.1), density (Choi), Standardized Uptake Value (
Kevin Zwirtz +7 more
doaj +1 more source
IJU Case Reports, Volume 9, Issue 4, July 2026.ABSTRACT Introduction 68Ga‐DOTATOC positron emission tomography/computed tomography (PET/CT) targets somatostatin receptors (SSTRs) and is an established molecular imaging modality for neuroendocrine tumors (NETs). Although SSTR expression has been reported in renal cell carcinoma (RCC), its clinical utility remains unclear. Case Presentation A 76‐year‐
Yuta Mine +9 more
wiley +1 more source
Biomedicines, 2022 Therapy options for advanced pancreatic neuroendocrine tumors (pNETs) include the mTOR inhibitor everolimus and peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE, however further optimization in the therapeutic landscape is required ...
Johannes Zellmer +10 more
doaj +1 more source
Neuroendocrine tumours through an epigenetic lens: Emerging insights for diagnosis and treatment
Journal of Neuroendocrinology, Volume 38, Issue 6, June 2026.Abstract Neuroendocrine tumours (NETs) are well‐differentiated epithelial neuroendocrine neoplasms that frequently develop in the small intestine, pancreas, and lungs. NETs originate from neuroendocrine cells specialized in hormone secretion implicated in a number of physiological processes.
Victoria Jacquot +4 more
wiley +1 more source
Frontiers in Oncology, 2019 Purpose: To develop a care process model for the delivery of peptide receptor radionuclide therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs ...
Pashtoon Murtaza Kasi +10 more
doaj +1 more source
Cancer Medicine, Volume 15, Issue 5, May 2026.NCCT radiomics for surufatinib efficacy prediction in HM‐NENs. ABSTRACT Background Hepatic metastatic neuroendocrine neoplasms (HM‐NENs) have few treatment biomarkers and low survival rates. We created a clinical‐radiomics fusion model based on non‐contrast computed tomography (NCCT) to predict Surufatinib efficacy in HM‐NENs.
Miaomiao Feng +5 more
wiley +1 more source
Frontiers in Oncology, 2021 IntroductionNeuroendocrine neoplasms including neuroendocrine tumors (NETs) are often diagnosed as primary disseminated or inoperable. In those cases, systemic extensive therapy is necessary, but radical treatment is unlikely.
Marta Opalińska +4 more
doaj +1 more source
Clinical Case Reports, Volume 14, Issue 5, May 2026.ABSTRACT Paragangliomas may appear biochemically silent, yet still behave as functional tumors with severe intraoperative consequences. Normal preoperative catecholamine screening does not exclude the risk of hypertensive crisis during surgery.
Abdul Basit +5 more
wiley +1 more source